Precipio CEO enrolls in long term stock purchase plan
May 23 2019 - 9:55AM
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO),
announced today that, as previously stated, Ilan Danieli,
Precipio’s CEO, has enrolled in a plan to purchase Precipio’s
common stock on the open market in accordance with Rule 10b5-1 of
the Securities and Exchange Act of 1934.
Rule 10b5-1 allows officers and directors to
enter into written, prearranged stock trading plans for the purpose
of purchasing (or selling) company stock on the open market when
they are in possession of material non-public information. Once
established, officers and directors have no discretion over
purchase or sales of stock under the plan and the pre-planned
trades shall be executed as prescribed by the plan without regard
for any subsequent material non-public information that the plan
participant may receive.
“As someone who is entirely invested in the
mission of our company, I’m delighted to have this vehicle that
will enable me to not only benefit financially from the long term
appreciation of the share price, but also to clearly signal to the
market my confidence in the future of our business, and my
commitment to what we are doing,” said Ilan Danieli, Precipio’s
CEO.
About Precipio
Precipio has built a platform designed to
eradicate the problem of misdiagnosis by harnessing the intellect,
expertise and technology developed within academic institutions and
delivering quality diagnostic information to physicians and their
patients worldwide. Through its collaborations with world-class
academic institutions specializing in cancer research, diagnostics
and treatment such as the Yale School of Medicine and Harvard’s
Dana-Farber Cancer Institute, Precipio offers a new standard of
diagnostic accuracy enabling the highest level of patient care. For
more information, please visit www.precipiodx.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements,” within the meaning of federal
securities laws including financial projections related thereto and
potential market opportunity, plans and prospects and other
statements containing the words “anticipate,” “intend,” “may,”
“plan,” “predict,” “will,” “would,” “could,” “should,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
The Company's actual results could differ materially from those
anticipated in these forward-looking statements as a result of
various factors. Factors that could cause future results to
materially differ from the recent results or those projected in
forward-looking statements include the known risks, uncertainties
and other factors described in the Definitive Proxy filed by the
Company on April 29, 2019, the Company’s Quarterly Report on Form
10-Q for the quarter ended March 31, 2019 and the Company’s Annual
Report on Form 10-K for the year ended December 31, 2018 as filed
on April 16, 2019 as well as the Company’s prior filings and from
time to time in the Company’s subsequent filings with the
Securities and Exchange Commission. Any change in such factors,
risks and uncertainties may cause the actual results, events and
performance to differ materially from those referred to in such
statements. All information in this press release is as of the date
of the release and the Company does not undertake any duty to
update this information, including any forward-looking statements,
unless required by law.
Inquiries:
investors@precipiodx.com
+1-203-787-7888
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Apr 2023 to Apr 2024